These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 19951881

  • 41. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [Abstract] [Full Text] [Related]

  • 42. Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles.
    Długosz-Danecka M, Szmit S, Kocurek A, Koźlik P, Giza A, Zimowska-Curyło D, Małkowski B, Sowa-Staszczak A, Kużdżał J, Jurczak W.
    Pol Arch Intern Med; 2019 Apr 30; 129(4):259-266. PubMed ID: 30945698
    [Abstract] [Full Text] [Related]

  • 43. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, Quittet P, Jais JP, Colonna P, Andrieu JM, Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang.
    Cancer; 2008 Dec 15; 113(12):3323-30. PubMed ID: 18988286
    [Abstract] [Full Text] [Related]

  • 44. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R.
    Cancer Treat Rep; 1984 Dec 15; 68(7-8):947-51. PubMed ID: 6204754
    [Abstract] [Full Text] [Related]

  • 45. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M, Ditonno P, Lorusso V, Timurian A, Pellecchia A, Brandi M, Berardi F, Marzullo F.
    Haematologica; 1993 Dec 15; 78(4):230-5. PubMed ID: 7507457
    [Abstract] [Full Text] [Related]

  • 46. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G.
    Cancer Treat Rep; 1986 Mar 15; 70(3):343-8. PubMed ID: 2420444
    [Abstract] [Full Text] [Related]

  • 47. [Thymus hyperplasia after chemotherapy in a case of Hodgkin's disease].
    Andreopoulos D, Klose KC, Glöckner WM.
    Rofo; 1991 Oct 15; 155(4):375-6. PubMed ID: 1718486
    [No Abstract] [Full Text] [Related]

  • 48. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
    von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A.
    J Clin Oncol; 2012 Mar 20; 30(9):907-13. PubMed ID: 22271480
    [Abstract] [Full Text] [Related]

  • 49. Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse).
    Ansell SM.
    Hematol Oncol Clin North Am; 2014 Feb 20; 28(1):75-86. PubMed ID: 24287069
    [Abstract] [Full Text] [Related]

  • 50. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD.
    Ragni G, Lombardi C, Santoro A, Bestetti O, Wyssling H.
    Acta Eur Fertil; 1983 Feb 20; 14(3):221-2. PubMed ID: 6199937
    [No Abstract] [Full Text] [Related]

  • 51. Long-term follow-up of survival in Hodgkin's lymphoma.
    Canellos GP, Niedzwiecki D, Johnson JL.
    N Engl J Med; 2009 Dec 10; 361(24):2390-1. PubMed ID: 20007568
    [No Abstract] [Full Text] [Related]

  • 52. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A.
    J Clin Oncol; 2005 Mar 01; 23(7):1522-9. PubMed ID: 15632410
    [Abstract] [Full Text] [Related]

  • 53. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
    Hehn ST, Miller TP.
    Curr Hematol Rep; 2004 Jan 01; 3(1):17-26. PubMed ID: 14695845
    [Abstract] [Full Text] [Related]

  • 54. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP.
    Anselmo AP, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M.
    Haematologica; 1990 Jan 01; 75(2):155-8. PubMed ID: 1694156
    [Abstract] [Full Text] [Related]

  • 55. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential.
    Sen P, Bailey NM, Hagemeister FB, Liang JC.
    Cancer Res; 1990 Feb 01; 50(3):558-62. PubMed ID: 1688733
    [Abstract] [Full Text] [Related]

  • 56. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
    Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.
    J Clin Oncol; 2010 May 01; 28(13):2239-45. PubMed ID: 20368566
    [Abstract] [Full Text] [Related]

  • 57. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.
    Wedgwood A, Younes A.
    Clin Lymphoma Myeloma; 2007 Dec 01; 8 Suppl 2():S63-6. PubMed ID: 18284718
    [Abstract] [Full Text] [Related]

  • 58. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P.
    Eur J Cancer; 2005 May 01; 41(7):998-1006. PubMed ID: 15862748
    [Abstract] [Full Text] [Related]

  • 59. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.
    Wen Q, Ge J, Lei Y, Zhang Y, Kong X, Wang W, Hou H, Wang Z, Qian S, Ding M, Dong M, Zhu L, Zhang M, Zhang X, Chen Q.
    J Cancer Res Clin Oncol; 2023 Jul 01; 149(7):3989-4003. PubMed ID: 36030432
    [Abstract] [Full Text] [Related]

  • 60. 'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma-A multicentre, retrospective study.
    Wilson MR, Haynes E, Parsons K, Hopkins D, Robertson E, Ferguson G, Quinn D, Murray J, Osborne W, Leach M, McKay P.
    Br J Haematol; 2023 Aug 01; 202(4):796-800. PubMed ID: 37357380
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.